A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Nilotinib (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Biomarker
- Acronyms PD Nilotinib
- 12 Jan 2022 Status changed from active, no longer recruiting to completed according to keiferx pipeline.
- 22 Apr 2021 Results (n=63) presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 20 Nov 2020 Results (n=63) of open-label extension part of this trial published in the Movement Disorders